New Drug Shows Promise in Maintaining Weight Loss and Muscle Mass After GLP-1 Use

Colorado-based biotech company Enveda has reported preliminary results on a novel drug designed to help patients maintain weight loss and preserve muscle mass after discontinuing GLP-1 medications like semaglutide. The drug works through a different mechanism than exercise but may complement lifestyle changes for sustained metabolic benefits. This addresses a significant clinical challenge where patients often regain weight and lose muscle tone after stopping GLP-1 therapy. The findings could offer hope for individuals struggling with weight management and body composition following anti-obesity treatment.